Localizing Labels and Instructions for Overseas Registration of Rehabilitation Devices: A Regulatory Compliance Guide

Published: August 14, 2026 | Updated: August 14, 2026

Key Summary

Localization of labels and instructions for overseas registration of rehabilitation devices is not simple translation; it requires technical adaptation based on the regulatory requirements of the target country. Companies should first confirm whether the product is regulated as a medical device in the target country, determine its risk class and registration pathway, and then review existing NMPA, CE, FDA, or other documentation to identify reusable content and items that must be localized.

The localization scope covers language, units of measurement, symbols, warnings, patient information, physician instructions, battery and electrical safety, radiation or biocompatibility information, and also must consider local culture, clinical practice, and regulatory review priorities. Common risks include performing only literal translation, ignoring local special warning requirements, failing to update registration certificate information, and not confirming change processes with the local agent.

Companies should initiate a localization gap analysis early in the project, establish version control for labels and instructions, and ensure linkage with post-market surveillance, adverse event reporting, and change notification processes. For Chinese medical device manufacturers, the prudent first step is to conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target market registration often impacts technical files, authorized representatives, importer cooperation, label language, quality system evidence, and ongoing change maintenance. If the project is approached merely as "which documents to submit," it is easy to face deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies address this issue within the framework of GHWP member countries and multi-national access strategies, using a single set of reusable core technical documents to support localization across different markets, rather than recreate documentation ad hoc for each country.

Applicable Scenarios and Core Issues

Rehabilitation devices include physical therapy equipment, exercise rehabilitation instruments, walking aids, wheelchairs, rehabilitation robots, electrical stimulators, ultrasound therapy devices, traction devices, and similar products. For these products overseas registration, labels and instructions are critical components of technical documentation, directly affecting whether the product can pass review, legally enter the market, and avoid regulatory penalties after launch.

The core problem companies often face is: after obtaining an NMPA registration certificate or CE certificate, they assume that translating the instructions into English or the local language is sufficient for submission. In reality, overseas regulators review labels and instructions not merely for language conversion; they require content, format, warnings, symbols, clinical claims, intended populations, contraindications, and other elements to comply with local laws and standards. Incomplete or misleading localization can lead to deficiencies, delayed approval, or even product recall.

Applicable scenarios include: entering a GHWP member country or target market for the first time, expanding to new markets with an existing CE or FDA registration, multi-country joint registration, and lifecycle changes to labels and instructions.

Regulatory Classification and Pathway Logic

Step 1: Determine Whether the Product Is Regulated as a Medical Device

Different countries classify products differently. Some rehabilitation devices may be classified as general consumer products, while others are medical devices. Companies should confirm via the target country's regulatory authority website or local agent.

Step 2: Determine Risk Class and Registration Pathway

Rehabilitation devices are typically Class I or II, though some implantable or high-energy devices may be Class III. Each class has different registration procedures, technical documentation depth, and label review stringency.

Step 3: Assess Reusability of Existing Documentation

If the company already holds an NMPA registration certificate, CE certificate, FDA 510(k), or MDSAP certificate, relevant technical files, test reports, and quality management system certificates can serve as a basis. However, it is necessary to verify whether these documents cover specific target country requirements, such as language, standard versions, and clinical evaluation expectations.

Step 4: Confirm the Localization Scope for Labels and Instructions

In addition to translation, companies must verify local regulations regarding marks, symbols, warnings, shelf life, production date, sterilization method, electromagnetic compatibility, biocompatibility, battery safety, and other details. Also, determine whether the local agent's or authorized representative's name, address, and contact information must appear on the label.

Step 5: Plan Post-Market Maintenance

Label and instruction localization is not a one-time effort. When product changes, standard updates, or regulatory requirement changes occur, the company must submit change applications through the local agent, update labels and instructions, and synchronize post-market surveillance documents.

Documentation and Evidence

Localization relies on a complete evidence chain. Companies should prepare the following documents:

• Labels and instructions from the country of origin
• Clinical evaluation or performance assessment reports
• Risk management reports
• Technical requirements or performance specifications
• Test reports
• ISO 13485 quality management system certificate
• Any existing CE, FDA, or NMPA labels and instructions

During localization, draft labels and instructions specific to the target country must be prepared, accompanied by item-by-item difference analysis. For example, does the target country use metric or imperial units? Are specific symbols required? Must warnings be presented in a particular language? Are specific font sizes mandated?

If the product includes software, wireless communication, batteries, or reusable parts, additional safety information and maintenance instructions are needed. For high-risk devices such as rehabilitation robots, clinical evidence and training programs may be required, and the instructions should include guidance for both professional operators and patients.

For multi-country registration, AIMEILI recommends establishing a core technical document library that separates reusable content from localized content, forming a structure of “core template + country-specific difference pages” to improve efficiency and reduce repeated deficiencies.

Common Errors

• Performing only language translation without regulatory difference analysis and content adjustment.
• Ignoring local units of measurement, date formats, and symbol standards. For example, the United States uses pounds and inches, while Europe uses kilograms and centimeters.
• Failing to display the local authorized representative or local agent information on the label, or displaying incorrect information.
• Blindly copying CE MDD/MDR label requirements without considering target country-specific warnings or contraindications.
• Providing clinical claims, such as “rehabilitation” benefits, without supporting clinical data.
• Neglecting the impact of post-market changes on labels and instructions, e.g., not updating instructions after material changes.
• Omitting label and instruction version control within the quality system, lacking version numbers and approval records.
• Not addressing target country UDI or traceability code requirements.

Preparation Checklist

• Establish a target country regulatory requirements list, including medical device definition, classification, and labeling/instruction requirements.
• Form a localization working group with regulatory, clinical, engineering, and quality personnel, and define responsibilities.
• Compile existing technical documentation and assess reusable content.
• Prepare a label and instruction localization gap analysis report.
• Develop a localization version control process to ensure consistency with registration certificates and technical files.
• Confirm the local agent and obtain the authorization letter and local registration entity information.
• Review labels and instructions item by item against the target country's official language and standard terminology.
• Complete internal review and approval, and retain records.
• Seek pre-review input from local consultants or regulatory authorities before submission.
• Establish a post-market change and update mechanism to ensure timely submission of new label versions to regulators.

AIMEILI Perspective

The most common misconception is that label and instruction localization for overseas registration is merely a translation task. In reality, this is a regulatory compliance activity that must be linked to product classification, registration pathway, technical documentation, quality systems, clinical evaluation, and post-market surveillance. AIMEILI recommends that companies conduct a localization gap analysis at the initial stage of the project, rather than waiting until testing and clinical work are completed.

Priorities at the outset should include confirming the target country's regulatory requirements and product classification, because if the product is classified at a higher risk level, label and instruction requirements will be significantly more stringent. Also, sign an agreement with the local agent at project initiation, clearly defining the agent's responsibilities in label and instruction review, change notifications, and regulatory communication. Certificate control is especially important; if the certificate is held by an overseas agent or distributor, the company may lose the ability to independently update labels and instructions.

Which documents can be reused? NMPA registration certificates, CE technical files, ISO 13485 certificates, and already-validated performance data can be reused, but they must be translated into the local language and format adjusted. What must be localized? Warnings, contraindications, special populations (e.g., children, pregnant women), intended environments (e.g., home, hospital, indoor/outdoor), electrical safety notices, wireless communication information, and disposal instructions all must be localized to meet local regulations and medical practice.

For multi-country registrations, AIMEILI strongly recommends building a “core template + regional differences” document structure. The headquarters centrally manages core content, while each region maintains only the difference pages. This significantly reduces redundant work and deficiency risks. Additionally, strict version control must be maintained, and every change must be synchronized with registration certificate information. The local agent is not an “errand runner” but an extension of the company's regulatory compliance, so it is essential to maintain clear communication channels with the agent at all times.

Additional FAQ Questions

Must labels and instructions be translated into all official languages of the target country?

Not necessarily. Some countries require all official languages to appear on labels and instructions, such as Canada, Switzerland, and Belgium; others require only one or two designated official languages. Companies should verify the target country's official language requirements and the actual user population, to avoid omissions or unnecessary costs.

Can existing CE labels and instructions be used directly for overseas registration?

No. CE labels and instructions are based on EU regulations and standards and may contain EU-specific symbols and warnings. The target country may use different standard versions, classification rules, and warning texts. Directly using CE versions often leads to deficiencies or rejection. AIMEILI recommends using the CE version as a baseline, performing a content gap analysis, and creating a target-country version.

What is the role of the local agent and authorized representative in labels and instructions?

The local agent is the company's legal contact in the target country, and its name and address typically must appear on labels and instructions. The agent assists with registration, facilitates regulatory communication, and assumes responsibility during the post-market phase. If the agent changes, the label and instructions must be updated and submitted to the regulator promptly; otherwise, the label may be considered inaccurate.

Continue Reading

For further guidance, explore these related articles:

• How to Prepare Technical Documentation for Overseas Registration of Rehabilitation Devices?
• Can Test Reports Be Reused for Overseas Registration of Rehabilitation Devices?
• How to Define the Responsibilities of an Authorized Representative for Monitoring Device Overseas Registration?
• How to Conduct Post-Market Surveillance for Overseas Registration of Monitoring Devices?
• What to Do When Quality System Evidence Is Inconsistent for Overseas Registration of Imaging Devices?

Content author: AIMEILI Regulatory Editorial Department
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies, and public regulatory materials; industry media and project experience are used as supplementary reference.
Applicability: This article is for preliminary understanding, documentation preparation, and project planning, and does not replace official requirements from target country regulators, test conclusions, or legal advice.